Carlos Costa - Sep 16, 2024 Form 4 Insider Report for Foghorn Therapeutics Inc. (FHTX)

Role
Chief People Officer
Signature
/s/ Michael LaCascia, Attorney-in-Fact for Carlos Costa
Stock symbol
FHTX
Transactions as of
Sep 16, 2024
Transactions value $
-$67,431
Form type
4
Date filed
9/18/2024, 04:01 PM
Previous filing
Jan 25, 2024
Next filing
Sep 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FHTX Common Stock Options Exercise $1.49K +400 $3.72 400 Sep 16, 2024 Direct F1
transaction FHTX Common Stock Sale -$4K -400 -100% $10.00 0 Sep 16, 2024 Direct F1
transaction FHTX Common Stock Options Exercise $38.2K +10.3K $3.72 10.3K Sep 17, 2024 Direct F1
transaction FHTX Common Stock Sale -$103K -10.3K -100% $10.04 0 Sep 17, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FHTX Stock Option (right to buy) Options Exercise $0 -400 -0.41% $0.00 98.2K Sep 16, 2024 Common Stock 400 $3.72 Direct F1, F3
transaction FHTX Stock Option (right to buy) Options Exercise $0 -10.3K -10.46% $0.00 88K Sep 17, 2024 Common Stock 10.3K $3.72 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 11, 2024.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $10.00 to $10.18 per share.
F3 The option vested as to 25% of the underlying shares of common stock on August 29, 2019, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter following such first anniversary until the option was fully vested.